Analysis updated Oct 24, 2026 — scores and signals refreshed daily.
Grifols, S.A. (GRFS) stock research. Updated Oct 24, 2026. Q-Score 38/100 — Sell. Fair value, forecast, technicals, and insider activity.
Current Q-Score verdict: Sell (38.0) (grade D). Gem alpha score: 33.0. 30 signals analyzed (26 differentiated alt-data).
StoQuant's analysis of Grifols, S.A. (GRFS) is refreshed every trading day. The Q-Score combines discounted cash flow valuation, earnings quality, competitive moat, analyst consensus, ML return forecasts, technical momentum and market sentiment into a single 0–100 composite. Insider transactions from SEC Form 4 filings, the Graham intrinsic value estimate and signal coverage are recomputed as new data arrives, so this page always reflects the latest available information.
GRFS stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-07-27 | $7.85 | $7.72 | $7.75 |
| 2026-08-04 | $8.14 | $7.91 | $8.07 |
| 2026-08-12 | $7.98 | $7.89 | $7.93 |
| 2026-08-20 | $8.20 | $7.97 | $7.99 |
| 2026-08-28 | $7.89 | $7.68 | $7.69 |
| 2026-09-08 | $7.83 | $7.74 | $7.75 |
| 2026-09-16 | $7.41 | $7.34 | $7.40 |
| 2026-09-24 | $7.28 | $7.15 | $7.20 |
| 2026-10-02 | $7.36 | $7.24 | $7.31 |
| 2026-10-12 | $7.52 | $7.36 | $7.37 |
| 2026-10-20 | $7.70 | $7.52 | $7.54 |
How Grifols, S.A. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| CNTA | Centessa Pharmaceuticals plc | $6.2B | — |
| ABVX | Abivax S.A. | $7.9B | — |
| BLCO | Bausch + Lomb Corporation | $5.8B | 62.0 |
| BLTE | Belite Bio, Inc | $5.7B | — |
| ICLR | ICON Public Limited Company | $8.8B | — |
View all Health Care stocks by valuation and signals →
Grifols, S.A. (GRFS) scores Sell (38.0), with every measured dimension at or below 43. The weakest are analyst consensus at 23, technicals at 22, AI Alpha (gem) at 2, across 4 measured dimensions. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| valuation | 43 |
| analyst consensus | 23 |
| technicals | 22 |
| AI Alpha (gem) | 2 |
StoQuant analyzes 30 signals (26 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Grifols, S.A. (GRFS): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
Browse daily research picks • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and IC-weighted signals (live edge on /proof). We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/GRFS"><img src="https://stoquant.com/badge/GRFS.svg" alt="Grifols, S.A. (GRFS) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Free StoQuant digest by email. No account needed. See today's research picks.